Download PDF
Hamostaseologie 2023; 43(01): 044-051
DOI: 10.1055/a-1980-8198
Review Article

Low von Willebrand Disease: A Bleeding Disorder of Unknown Cause?

James S. O'Donnell 
1   Irish Centre for Vascular Biology, School of Pharmacy and Biomolecular Sciences, Royal College of Surgeons in Ireland, Dublin 2, Ireland
2   National Coagulation Centre, St James's Hospital, Dublin, Ireland
3   Irish-Australian Blood Collaborative (IABC) Network, Dublin, Ireland
,
Ross I. Baker
3   Irish-Australian Blood Collaborative (IABC) Network, Dublin, Ireland
4   Western Australia Centre for Thrombosis and Haemostasis, Perth Blood Institute, Murdoch University, Perth, Australia
5   Hollywood Haemophilia Treatment Centre, Hollywood Hospital, Perth, Australia
› Author Affiliations Funding Science Foundation Ireland, Frontiers for the Future (FFP) Award (20/FFP-A/895)
› Further Information
Also available at
   Permissions and Reprints

Abstract

von Willebrand disease (VWD) represents the most common inherited bleeding disorder. The majority of VWD cases are characterized by partial quantitative reductions in plasma von Willebrand factor (VWF) levels. Management of patients with mild to moderate VWF reductions in the range of 30 to 50 IU/dL poses a common clinical challenge. Some of these low VWF patients present with significant bleeding problems. In particular, heavy menstrual bleeding and postpartum hemorrhage can cause significant morbidity. Conversely, however, many individuals with mild plasma VWF:Ag reductions do not have any bleeding sequelae. In contrast to type 1 VWD, most patients with low VWF do not have detectable pathogenic VWF sequence variants, and bleeding phenotype correlates poorly with residual VWF levels. These observations suggest that low VWF is a complex disorder caused by variants in other genes beyond VWF. With respect to low VWF pathobiology, recent studies have shown that reduced VWF biosynthesis within endothelial cells likely plays a key role. However, pathological enhanced VWF clearance from plasma has also been described in approximately 20% of low VWF cases. For low VWF patients who require hemostatic treatment prior to elective procedures, tranexamic acid and desmopressin have both been shown to be efficacious. In this article, we review the current state of the art regarding low VWF. In addition, we consider how low VWF represents an entity that appears to fall between type 1 VWD on the one hand and bleeding disorders of unknown cause on the other.

Keywords

von Willebrand factor - von Willebrand disease - low VWF

Authors' Contribution

R.I.B. and J.S.O'D. were involved in writing and reviewing the paper.




Publication History

Received: 02 October 2022

Accepted: 15 November 2022

Article published online:
20 February 2023

© 2023. Thieme. All rights reserved.

Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany

 

  • References

  • 1 Leebeek FW, Eikenboom JC. von Willebrand's disease. N Engl J Med 2016; 375 (21) 2067-2080
    CrossrefPubMedGoogle Scholar
  • 2 Bowman M, Hopman WM, Rapson D, Lillicrap D, James P. The prevalence of symptomatic von Willebrand disease in primary care practice. J Thromb Haemost 2010; 8 (01) 213-216
    CrossrefPubMedGoogle Scholar
  • 3 Laffan MA, Lester W, O'Donnell JS. et al. The diagnosis and management of von Willebrand disease: a United Kingdom Haemophilia Centre Doctors Organization guideline approved by the British Committee for Standards in Haematology. Br J Haematol 2014; 167 (04) 453-465
    CrossrefPubMedGoogle Scholar
  • 4 Castaman G, Goodeve A, Eikenboom J. European Group on von Willebrand Disease. Principles of care for the diagnosis and treatment of von Willebrand disease. Haematologica 2013; 98 (05) 667-674
    CrossrefPubMedGoogle Scholar
  • 5 Nichols WL, Hultin MB, James AH. et al. von Willebrand disease (VWD): evidence-based diagnosis and management guidelines, the National Heart, Lung, and Blood Institute (NHLBI) Expert Panel report (USA). Haemophilia 2008; 14 (02) 171-232
    CrossrefPubMedGoogle Scholar
  • 6 James PD, Connell NT, Ameer B. et al. ASH ISTH NHF WFH 2021 guidelines on the diagnosis of von Willebrand disease. Blood Adv 2021; 5 (01) 280-300
    CrossrefPubMedGoogle Scholar
  • 7 Fogarty H, Doherty D, O'Donnell JS. New developments in von Willebrand disease. Br J Haematol 2020; 191 (03) 329-339
    CrossrefPubMedGoogle Scholar
  • 8 de Wee EM, Sanders YV, Mauser-Bunschoten EP. et al; WiN Study Group. Determinants of bleeding phenotype in adult patients with moderate or severe von Willebrand disease. Thromb Haemost 2012; 108 (04) 683-692
    Article in Thieme ConnectPubMedGoogle Scholar
  • 9 Sanders YV, Fijnvandraat K, Boender J. et al; WiN Study Group. Bleeding spectrum in children with moderate or severe von Willebrand disease: relevance of pediatric-specific bleeding. Am J Hematol 2015; 90 (12) 1142-1148
    CrossrefPubMedGoogle Scholar
  • 10 Lavin M, Aguila S, Dalton N. et al. Significant gynecological bleeding in women with low von Willebrand factor levels. Blood Adv 2018; 2 (14) 1784-1791
    CrossrefPubMedGoogle Scholar
  • 11 Srivaths L, Minard CG, O'Brien SH. et al. The spectrum and severity of bleeding in adolescents with low von Willebrand factor-associated heavy menstrual bleeding. Blood Adv 2020; 4 (13) 3209-3216
    CrossrefPubMedGoogle Scholar
  • 12 Connell NT, James PD, Brignardello-Petersen R. et al. von Willebrand disease: proposing definitions for future research. Blood Adv 2021; 5 (02) 565-569
    PubMedGoogle Scholar
  • 13 Castaman G, Federici AB, Tosetto A. et al. Different bleeding risk in type 2A and 2M von Willebrand disease: a 2-year prospective study in 107 patients. J Thromb Haemost 2012; 10 (04) 632-638
    CrossrefPubMedGoogle Scholar
  • 14 Turecek PL, Johnsen JM, Pipe SW, O'Donnell JS. iPATH Study Group. Biological mechanisms underlying inter-individual variation in factor VIII clearance in haemophilia. Haemophilia 2020; 26 (04) 575-583
    CrossrefPubMedGoogle Scholar
  • 15 van Galen KP, Mauser-Bunschoten EP, Leebeek FW. Hemophilic arthropathy in patients with von Willebrand disease. Blood Rev 2012; 26 (06) 261-266
    CrossrefPubMedGoogle Scholar
  • 16 Ward SE, O'Sullivan JM, O'Donnell JS. The relationship between ABO blood group, von Willebrand factor, and primary hemostasis. Blood 2020; 136 (25) 2864-2874
    CrossrefPubMedGoogle Scholar
  • 17 Gill JC, Endres-Brooks J, Bauer PJ, Marks Jr WJ, Montgomery RR. The effect of ABO blood group on the diagnosis of von Willebrand disease. Blood 1987; 69 (06) 1691-1695
    CrossrefPubMedGoogle Scholar
  • 18 Gallinaro L, Cattini MG, Sztukowska M. et al. A shorter von Willebrand factor survival in O blood group subjects explains how ABO determinants influence plasma von Willebrand factor. Blood 2008; 111 (07) 3540-3545
    CrossrefPubMedGoogle Scholar
  • 19 Sadler JE. Low von Willebrand factor: sometimes a risk factor and sometimes a disease. Hematology (Am Soc Hematol Educ Program) 2009; 106-112
    CrossrefPubMedGoogle Scholar
  • 20 Sadler JE. Von Willebrand disease type 1: a diagnosis in search of a disease. Blood 2003; 101 (06) 2089-2093
    CrossrefPubMedGoogle Scholar
  • 21 Sadler JE. Slippery criteria for von Willebrand disease type 1. J Thromb Haemost 2004; 2 (10) 1720-1723
    CrossrefPubMedGoogle Scholar
  • 22 O'Donnell JS. Low VWF: insights into pathogenesis, diagnosis, and clinical management. Blood Adv 2020; 4 (13) 3191-3199
    CrossrefPubMedGoogle Scholar
  • 23 Cumming A, Grundy P, Keeney S. et al; UK Haemophilia Centre Doctors' Organisation. An investigation of the von Willebrand factor genotype in UK patients diagnosed to have type 1 von Willebrand disease. Thromb Haemost 2006; 96 (05) 630-641
    PubMedGoogle Scholar
  • 24 Goodeve A, Eikenboom J, Castaman G. et al. Phenotype and genotype of a cohort of families historically diagnosed with type 1 von Willebrand disease in the European study, Molecular and Clinical Markers for the Diagnosis and Management of Type 1 von Willebrand Disease (MCMDM-1VWD). Blood 2007; 109 (01) 112-121
    CrossrefPubMedGoogle Scholar
  • 25 James PD, Notley C, Hegadorn C. et al. The mutational spectrum of type 1 von Willebrand disease: results from a Canadian cohort study. Blood 2007; 109 (01) 145-154
    CrossrefPubMedGoogle Scholar
  • 26 Lavin M, Aguila S, Schneppenheim S. et al. Novel insights into the clinical phenotype and pathophysiology underlying low VWF levels. Blood 2017; 130 (21) 2344-2353
    CrossrefPubMedGoogle Scholar
  • 27 Flood VH, Christopherson PA, Gill JC. et al. Clinical and laboratory variability in a cohort of patients diagnosed with type 1 VWD in the United States. Blood 2016; 127 (20) 2481-2488
    CrossrefPubMedGoogle Scholar
  • 28 Gill JC, Conley SF, Johnson VP. et al. Low VWF levels in children and lack of association with bleeding in children undergoing tonsillectomy. Blood Adv 2020; 4 (01) 100-105
    CrossrefPubMedGoogle Scholar
  • 29 James PD, Paterson AD, Notley C. et al; Association of Hemophilia Clinic Directors of Canada. Genetic linkage and association analysis in type 1 von Willebrand disease: results from the Canadian type 1 VWD study. J Thromb Haemost 2006; 4 (04) 783-792
    CrossrefPubMedGoogle Scholar
  • 30 Eikenboom J, Van Marion V, Putter H. et al. Linkage analysis in families diagnosed with type 1 von Willebrand disease in the European study, molecular and clinical markers for the diagnosis and management of type 1 VWD. J Thromb Haemost 2006; 4 (04) 774-782
    CrossrefPubMedGoogle Scholar
  • 31 Kalot MA, Al-Khatib M, Connell NT. et al; VWD Working Group. An international survey to inform priorities for new guidelines on von Willebrand disease. Haemophilia 2020; 26 (01) 106-116
    CrossrefPubMedGoogle Scholar
  • 32 Kalot MA, Husainat N, El Alayli A. et al. von Willebrand factor levels in the diagnosis of von Willebrand disease: a systematic review and meta-analysis. Blood Adv 2022; 6 (01) 62-71
    CrossrefPubMedGoogle Scholar
  • 33 Makris M, Hermans C. The 2021 von Willebrand disease guidelines: clarity and controversy. Haemophilia 2022; 28 (01) 1-3
    CrossrefPubMedGoogle Scholar
  • 34 James PD, Connell NT, Flood VH, Mustafa RA. Response to “The 2021 von Willebrand disease guidelines: clarity and controversy”. Haemophilia 2022; 28 (03) 371-372
    CrossrefPubMedGoogle Scholar
  • 35 Swystun LL, Lillicrap D. Genetic regulation of plasma von Willebrand factor levels in health and disease. J Thromb Haemost 2018; 16 (12) 2375-2390
    CrossrefPubMedGoogle Scholar
  • 36 Sadler B, Christopherson PA, Haller G, Montgomery RR, Di Paola J. von Willebrand factor antigen levels are associated with burden of rare nonsynonymous variants in the VWF gene. Blood 2021; 137 (23) 3277-3283
    CrossrefPubMedGoogle Scholar
  • 37 de Jong A, Eikenboom J. Von Willebrand disease mutation spectrum and associated mutation mechanisms. Thromb Res 2017; 159: 65-75
    CrossrefPubMedGoogle Scholar
  • 38 Casonato A, Cattini MG, Daidone V, Pontara E, Bertomoro A, Prandoni P. Diagnostic value of measuring platelet von Willebrand factor in von Willebrand disease. PLoS One 2016; 11 (08) e0161310
    CrossrefPubMedGoogle Scholar
  • 39 Ng CJ, Liu A, Venkataraman S. et al. Single-cell transcriptional analysis of human endothelial colony-forming cells from patients with low VWF levels. Blood 2022; 139 (14) 2240-2251
    CrossrefPubMedGoogle Scholar
  • 40 O'Sullivan JM, Ward S, Lavin M, O'Donnell JS. von Willebrand factor clearance - biological mechanisms and clinical significance. Br J Haematol 2018; 183 (02) 185-195
    CrossrefPubMedGoogle Scholar
  • 41 Rastegarlari G, Pegon JN, Casari C. et al. Macrophage LRP1 contributes to the clearance of von Willebrand factor. Blood 2012; 119 (09) 2126-2134
    CrossrefPubMedGoogle Scholar
  • 42 Swystun LL, Lai JD, Notley C. et al. The endothelial cell receptor stabilin-2 regulates VWF-FVIII complex half-life and immunogenicity. J Clin Invest 2018; 128 (09) 4057-4073
    CrossrefPubMedGoogle Scholar
  • 43 Ward SE, O'Sullivan JM, Drakeford C. et al. A novel role for the macrophage galactose-type lectin receptor in mediating von Willebrand factor clearance. Blood 2018; 131 (08) 911-916
    CrossrefPubMedGoogle Scholar
  • 44 Wohner N, Muczynski V, Mohamadi A. et al. Macrophage scavenger receptor SR-AI contributes to the clearance of von Willebrand factor. Haematologica 2018; 103 (04) 728-737
    CrossrefPubMedGoogle Scholar
  • 45 Eikenboom J, Federici AB, Dirven RJ. et al; MCMDM-1VWD Study Group. VWF propeptide and ratios between VWF, VWF propeptide, and FVIII in the characterization of type 1 von Willebrand disease. Blood 2013; 121 (12) 2336-2339
    CrossrefPubMedGoogle Scholar
  • 46 Sanders YV, Groeneveld D, Meijer K. et al; WiN Study Group. von Willebrand factor propeptide and the phenotypic classification of von Willebrand disease. Blood 2015; 125 (19) 3006-3013
    CrossrefPubMedGoogle Scholar
  • 47 Haberichter SL, Balistreri M, Christopherson P. et al. Assay of the von Willebrand factor (VWF) propeptide to identify patients with type 1 von Willebrand disease with decreased VWF survival. Blood 2006; 108 (10) 3344-3351
    CrossrefPubMedGoogle Scholar
  • 48 Haberichter SL, Castaman G, Budde U. et al. Identification of type 1 von Willebrand disease patients with reduced von Willebrand factor survival by assay of the VWF propeptide in the European study: molecular and clinical markers for the diagnosis and management of type 1 VWD (MCMDM-1VWD). Blood 2008; 111 (10) 4979-4985
    CrossrefPubMedGoogle Scholar
  • 49 Casonato A, Pontara E, Sartorello F. et al. Reduced von Willebrand factor survival in type Vicenza von Willebrand disease. Blood 2002; 99 (01) 180-184
    CrossrefPubMedGoogle Scholar
  • 50 Doherty D, Lavin M, Byrne MB. et al. Enhanced VWF clearance in Low VWF pathogenesis - limitations of VWFpp/VWF:Ag ratio and clinical significance. Blood Adv 2022:bloodadvances.2022007340
    PubMedGoogle Scholar
  • 51 Aguila S, Lavin M, Dalton N. et al. Increased galactose expression and enhanced clearance in patients with low von Willebrand factor. Blood 2019; 133 (14) 1585-1596
    CrossrefPubMedGoogle Scholar
  • 52 Ward S, O'Sullivan JM, O'Donnell JS. von Willebrand factor sialylation - a critical regulator of biological function. J Thromb Haemost 2019; 17 (07) 1018-1029
    CrossrefPubMedGoogle Scholar
  • 53 van Schooten CJ, Denis CV, Lisman T. et al. Variations in glycosylation of von Willebrand factor with O-linked sialylated T antigen are associated with its plasma levels. Blood 2007; 109 (06) 2430-2437
    CrossrefPubMedGoogle Scholar
  • 54 Sadler B, Minard CG, Haller G. et al. Whole-exome analysis of adolescents with low VWF and heavy menstrual bleeding identifies novel genetic associations. Blood Adv 2022; 6 (02) 420-428
    CrossrefPubMedGoogle Scholar
  • 55 Lavin M, O'Donnell JS. How I treat low von Willebrand factor levels. Blood 2019; 133 (08) 795-804
    CrossrefPubMedGoogle Scholar
  • 56 Lavin M, O'Donnell JS. New treatment approaches to von Willebrand disease. Hematology (Am Soc Hematol Educ Program) 2016; 2016 (01) 683-689
    CrossrefPubMedGoogle Scholar
  • 57 Connell NT, Flood VH, Brignardello-Petersen R. et al. ASH ISTH NHF WFH 2021 guidelines on the management of von Willebrand disease. Blood Adv 2021; 5 (01) 301-325
    CrossrefPubMedGoogle Scholar
  • 58 Doherty D, Lavin M, O'Sullivan JM. et al. Management of elective procedures in low von Willebrand factor patients in the LoVIC study. J Thromb Haemost 2021; 19 (03) 701-710
    CrossrefPubMedGoogle Scholar
  • 59 Castaman G, Lethagen S, Federici AB. et al. Response to desmopressin is influenced by the genotype and phenotype in type 1 von Willebrand disease (VWD): results from the European Study MCMDM-1VWD. Blood 2008; 111 (07) 3531-3539
    CrossrefPubMedGoogle Scholar
  • 60 Albánez S, Ogiwara K, Michels A. et al. Aging and ABO blood type influence von Willebrand factor and factor VIII levels through interrelated mechanisms. J Thromb Haemost 2016; 14 (05) 953-963
    CrossrefPubMedGoogle Scholar
  • 61 Rydz N, Grabell J, Lillicrap D, James PD. Changes in von Willebrand factor level and von Willebrand activity with age in type 1 von Willebrand disease. Haemophilia 2015; 21 (05) 636-641
    CrossrefPubMedGoogle Scholar
  • 62 Sanders YV, Giezenaar MA, Laros-van Gorkom BA. et al; WiN Study Group. von Willebrand disease and aging: an evolving phenotype. J Thromb Haemost 2014; 12 (07) 1066-1075
    CrossrefPubMedGoogle Scholar
  • 63 Atiq F, Meijer K, Eikenboom J. et al; WiN Study Group. Comorbidities associated with higher von Willebrand factor (VWF) levels may explain the age-related increase of VWF in von Willebrand disease. Br J Haematol 2018; 182 (01) 93-105
    CrossrefPubMedGoogle Scholar
  • 64 O'Donnell JS, O'Sullivan JM, Preston RJS. Advances in understanding the molecular mechanisms that maintain normal haemostasis. Br J Haematol 2019; 186 (01) 24-36
    CrossrefPubMedGoogle Scholar
  • 65 Atiq F, Wuijster E, de Maat MPM, Kruip MJHA, Cnossen MH, Leebeek FWG. Criteria for low von Willebrand factor diagnosis and risk score to predict future bleeding. J Thromb Haemost 2021; 19 (03) 719-731
    CrossrefPubMedGoogle Scholar
  • 66 Baker RI, O'Donnell JS. How I treat bleeding disorder of unknown cause. Blood 2021; 138 (19) 1795-1804
    CrossrefPubMedGoogle Scholar